Advertisement Pharmaceutical Business review - Page 27 of 5274 -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
May 25, 2026

AstraZeneca, Daiichi Sankyo’s Datroway receives FDA approval for TNBC

AstraZeneca and Daiichi Sankyo have secured approval from the US Food and Drug Administration (FDA) for Datroway (datopotamab deruxtecan) to treat metastatic triple-negative breast cancer (TNBC).

The trial reported a 43% reduction in disease progression or death and an ORR of 64% versus 30% chemotherapy. Credit: 89stocker/Shutterstock.com.